AT506820B1 - Vakzine gegen alzheimer-krankheit - Google Patents

Vakzine gegen alzheimer-krankheit Download PDF

Info

Publication number
AT506820B1
AT506820B1 AT0095208A AT9522008A AT506820B1 AT 506820 B1 AT506820 B1 AT 506820B1 AT 0095208 A AT0095208 A AT 0095208A AT 9522008 A AT9522008 A AT 9522008A AT 506820 B1 AT506820 B1 AT 506820B1
Authority
AT
Austria
Prior art keywords
peptide
mimotope
amino acid
compound
prt
Prior art date
Application number
AT0095208A
Other languages
German (de)
English (en)
Other versions
AT506820A1 (de
Original Assignee
Affiris Forschungs Und Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ATA416/2010A priority Critical patent/AT509611B1/de
Application filed by Affiris Forschungs Und Entwicklungs Gmbh filed Critical Affiris Forschungs Und Entwicklungs Gmbh
Priority to AT0095208A priority patent/AT506820B1/de
Priority to JP2011512782A priority patent/JP2011522842A/ja
Priority to BRPI0915134A priority patent/BRPI0915134A2/pt
Priority to MX2010013657A priority patent/MX2010013657A/es
Priority to EP09761152A priority patent/EP2310033B1/en
Priority to CA2723995A priority patent/CA2723995A1/en
Priority to BRPI0915136A priority patent/BRPI0915136A2/pt
Priority to US12/997,673 priority patent/US8409581B2/en
Priority to PCT/AT2009/000235 priority patent/WO2009149485A2/en
Priority to PCT/AT2009/000237 priority patent/WO2009149487A2/en
Priority to CN2009801313674A priority patent/CN102123726A/zh
Priority to AU2009257170A priority patent/AU2009257170B2/en
Priority to MX2010013647A priority patent/MX2010013647A/es
Priority to JP2011512780A priority patent/JP2011522840A/ja
Priority to RU2011100127/15A priority patent/RU2011100127A/ru
Priority to US12/997,702 priority patent/US20110092436A1/en
Priority to CN200980131376.3A priority patent/CN102123728B/zh
Priority to AU2009257168A priority patent/AU2009257168B2/en
Priority to KR1020117000810A priority patent/KR20110036039A/ko
Priority to CA2723967A priority patent/CA2723967A1/en
Priority to ES09761152T priority patent/ES2392789T3/es
Priority to EP20090761154 priority patent/EP2310032A2/en
Priority to KR1020117000819A priority patent/KR20110036809A/ko
Priority to RU2011100125/15A priority patent/RU2491953C2/ru
Publication of AT506820A1 publication Critical patent/AT506820A1/de
Priority to IL209894A priority patent/IL209894A/en
Priority to IL209896A priority patent/IL209896A0/en
Application granted granted Critical
Publication of AT506820B1 publication Critical patent/AT506820B1/de
Priority to US13/770,594 priority patent/US20130287807A1/en
Priority to JP2014073229A priority patent/JP5984867B2/ja
Priority to JP2014263345A priority patent/JP5989074B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT0095208A 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit AT506820B1 (de)

Priority Applications (30)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA416/2010A AT509611B1 (de) 2008-06-12 2008-06-12 Vakzin
US12/997,702 US20110092436A1 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
MX2010013657A MX2010013657A (es) 2008-06-12 2009-06-12 Compuestos para tratar la amiloidosis.
EP09761152A EP2310033B1 (en) 2008-06-12 2009-06-12 Peptide compounds for treating amyloidoses
CA2723995A CA2723995A1 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
BRPI0915136A BRPI0915136A2 (pt) 2008-06-12 2009-06-12 uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
US12/997,673 US8409581B2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses
PCT/AT2009/000235 WO2009149485A2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses
PCT/AT2009/000237 WO2009149487A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
CN2009801313674A CN102123726A (zh) 2008-06-12 2009-06-12 用于治疗与帕金森氏病有关的症状的化合物
AU2009257170A AU2009257170B2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with Parkinson's disease
MX2010013647A MX2010013647A (es) 2008-06-12 2009-06-12 Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
JP2011512780A JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物
JP2011512782A JP2011522842A (ja) 2008-06-12 2009-06-12 パーキンソン病に関連する症状の治療のための化合物
CN200980131376.3A CN102123728B (zh) 2008-06-12 2009-06-12 用于治疗淀粉样变的化合物
CA2723967A CA2723967A1 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses
BRPI0915134A BRPI0915134A2 (pt) 2008-06-12 2009-06-12 composto, e, uso de um composto
KR1020117000810A KR20110036039A (ko) 2008-06-12 2009-06-12 아밀로이드증을 치료하기 위한 화합물
AU2009257168A AU2009257168B2 (en) 2008-06-12 2009-06-12 Compounds for treating Amyloidoses
ES09761152T ES2392789T3 (es) 2008-06-12 2009-06-12 Compuestos peptídicos para tratar las amiloidosis.
EP20090761154 EP2310032A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
KR1020117000819A KR20110036809A (ko) 2008-06-12 2009-06-12 파킨슨병과 관련된 증상을 치료하기 위한 화합물
RU2011100125/15A RU2491953C2 (ru) 2008-06-12 2009-06-12 Соединения для лечения амилоидозов
RU2011100127/15A RU2011100127A (ru) 2008-06-12 2009-06-12 Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
IL209894A IL209894A (en) 2008-06-12 2010-12-09 Compounds for the prevention and / or treatment of β-amyloidosis including Alzheimer's disease
IL209896A IL209896A0 (en) 2008-06-12 2010-12-09 Compounds for treating symptoms associated with parkinson's disease
US13/770,594 US20130287807A1 (en) 2008-06-12 2013-02-19 Compounds for treating symptoms associated with parkinson's disease
JP2014073229A JP5984867B2 (ja) 2008-06-12 2014-03-31 アミロイドーシス治療のための化合物
JP2014263345A JP5989074B2 (ja) 2008-06-12 2014-12-25 アミロイドーシス治療のための化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit

Publications (2)

Publication Number Publication Date
AT506820A1 AT506820A1 (de) 2009-12-15
AT506820B1 true AT506820B1 (de) 2011-07-15

Family

ID=41401983

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA416/2010A AT509611B1 (de) 2008-06-12 2008-06-12 Vakzin

Family Applications After (1)

Application Number Title Priority Date Filing Date
ATA416/2010A AT509611B1 (de) 2008-06-12 2008-06-12 Vakzin

Country Status (14)

Country Link
US (1) US8409581B2 (enExample)
EP (1) EP2310033B1 (enExample)
JP (3) JP2011522840A (enExample)
KR (1) KR20110036039A (enExample)
CN (1) CN102123728B (enExample)
AT (2) AT506820B1 (enExample)
AU (1) AU2009257168B2 (enExample)
BR (1) BRPI0915136A2 (enExample)
CA (1) CA2723967A1 (enExample)
ES (1) ES2392789T3 (enExample)
IL (1) IL209894A (enExample)
MX (1) MX2010013657A (enExample)
RU (1) RU2491953C2 (enExample)
WO (1) WO2009149485A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CN103459421B (zh) 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
DK3137094T3 (da) 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
MX2021008035A (es) 2018-12-31 2021-12-10 United Neuroscience Ltd Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
CN115925987B (zh) * 2022-02-28 2026-05-05 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002510641A (ja) * 1998-04-06 2002-04-09 アドヴァンスト・イミューニット・インク 神経退化疾患治療用短ペプチド
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
ES2345746T3 (es) * 1998-05-21 2010-09-30 University Of Tennessee Research Foundation Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CA2790433A1 (en) * 2004-10-25 2006-05-26 Northwestern University Anti-addl antibodies and uses thereof
WO2006136906A2 (en) * 2005-06-17 2006-12-28 Epfl Ecole Polytechnique Fédérale De Lausanne Switch-peptides as tool for the study of fibrillogenesis
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
CN101421299A (zh) * 2006-02-22 2009-04-29 株式会社林原生物化学研究所 用于诱导产生抗淀粉样β肽抗体的肽疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes

Also Published As

Publication number Publication date
IL209894A0 (en) 2011-02-28
US20110171243A1 (en) 2011-07-14
AT509611A1 (de) 2011-10-15
ES2392789T3 (es) 2012-12-13
EP2310033B1 (en) 2012-09-05
JP2015110588A (ja) 2015-06-18
RU2491953C2 (ru) 2013-09-10
RU2011100125A (ru) 2012-07-20
AU2009257168B2 (en) 2015-01-22
US8409581B2 (en) 2013-04-02
WO2009149485A3 (en) 2010-06-10
AT506820A1 (de) 2009-12-15
AU2009257168A1 (en) 2009-12-17
AT509611B1 (de) 2012-04-15
JP5984867B2 (ja) 2016-09-06
BRPI0915136A2 (pt) 2019-09-24
WO2009149485A2 (en) 2009-12-17
JP5989074B2 (ja) 2016-09-07
IL209894A (en) 2015-08-31
CN102123728A (zh) 2011-07-13
MX2010013657A (es) 2011-04-11
EP2310033A2 (en) 2011-04-20
JP2011522840A (ja) 2011-08-04
JP2014139227A (ja) 2014-07-31
CN102123728B (zh) 2017-05-31
KR20110036039A (ko) 2011-04-06
CA2723967A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
AT509611B1 (de) Vakzin
AT509106B1 (de) Vakzin zur behandlung von alzheimer krankheit
AT506535B1 (de) Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
HK1152470B (en) Peptides for treating beta-amyloidoses

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20160612